Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares

Reuters

2025/12/10

Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares

Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590373878"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590373878\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590373878?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590373878","market":"nz","top_or_hot":-1,"title":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 08:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6WJy9c:1","article_id":"2590373878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590373878","pubTimestamp":1765326446,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein  monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 , which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01911":"华兴资本控股","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1161":"生物科技","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","01801":"信达生物","BK1147":"投资银行业与经纪业","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC"},"translate_title":"信达生物为抗IL-1RAP抗体治疗痛风发作的1期试验中的首例参与者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares\n    \n\nInnovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein (IL-1RAP) monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 (tigulixostat), which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42190) on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}